Momenta Pharmaceuticals (NASDAQ:MNTA) Receiving Somewhat Favorable News Coverage, Study Finds
Headlines about Momenta Pharmaceuticals (NASDAQ:MNTA) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Momenta Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.0490037909053 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s analysis:
- See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. (finance.yahoo.com)
- Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : August 12, 2017 (finance.yahoo.com)
- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- IHS Markit Score downgrades Momenta Pharmaceuticals Inc to 30 out of 100, ranking positively in only one out of three available IHS Markit categories. (finance.yahoo.com)
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 15.90 on Friday. Momenta Pharmaceuticals has a 1-year low of $10.66 and a 1-year high of $19.90. The stock’s market cap is $1.18 billion. The firm’s 50-day moving average price is $16.80 and its 200 day moving average price is $15.69.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The company had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The business’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.31) earnings per share. On average, equities analysts expect that Momenta Pharmaceuticals will post ($1.20) earnings per share for the current fiscal year.
Several research analysts recently weighed in on the company. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Stifel Nicolaus restated a “buy” rating and set a $26.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. Aegis restated a “hold” rating and set a $17.00 target price on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 3rd. Finally, Maxim Group set a $6.00 target price on Momenta Pharmaceuticals and gave the stock a “sell” rating in a research note on Wednesday, May 3rd. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $16.63.
COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/08/13/momenta-pharmaceuticals-nasdaqmnta-receiving-somewhat-favorable-news-coverage-study-finds.html.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $15.83, for a total transaction of $65,156.28. Following the transaction, the president now owns 281,919 shares of the company’s stock, valued at $4,462,777.77. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 5,996 shares of company stock worth $94,323. Corporate insiders own 4.40% of the company’s stock.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.